It can be antioncogenic by reducing the damaging effects of aldehydes, and promoting signaling cell survival especially in hepatocellular carcinoma.[22, 23] However, some studies suggest that ALDH2 overexpression or high activity promotes cancer progression and MDR in clear‐cell renal cell carcinomas (ccRCC) and bladder cancer.[24, 25] Our study also indicates that downregulation of ALDH2 was shown to increase tumor infiltration of CD3+ and CD8+ T lymphocytes and significantly suppress tumor growth and progression in our murine CRC model (Figure 2). Here, CD8A is linked to urinary bladder carcinoma.